---
title: "Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290691174.md"
description: "Calidi Biotherapeutics presented new preclinical data on CLD-501, a TROP2-targeting T-cell engager, at the T-Cell Engager Therapeutic Summit. The data supports localized in-tumor expression to limit off-tumor toxicity. Additionally, the company highlighted progress on its RedTail platform, with lead candidate CLD-401 targeting an IND filing by end-2026."
datetime: "2026-06-24T12:00:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290691174.md)
  - [en](https://longbridge.com/en/news/290691174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290691174.md)
---

# Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summit

-   Calidi Biotherapeutics presented new preclinical data on June 24, 2026 for CLD-501, a tumor-targeted T-cell engager program aimed at TROP-2. \* Results were already presented at the T-Cell Engager Therapeutic Summit, outlining an approach designed to activate T-cells within solid tumors. \* Data supported localized, in-tumor expression intended to limit off-tumor toxicity risk that has constrained TROP-2 T-cell engager development. \* The update also highlighted RedTail platform progress, with CLD-401 positioned as the lead candidate and an IND filing targeted by end-2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240800PRIMZONEFULLFEED9751622) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)

## Related News & Research

- [Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board](https://longbridge.com/en/news/293337933.md)
- [Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, Kentucky](https://longbridge.com/en/news/293334323.md)
- [Major Investor Quietly Boosts Position in Oncology Powerhouse](https://longbridge.com/en/news/293546905.md)
- [Quest Diagnostics (DGX) Expands Oncology Test Access, Is The Stock Fully Valued?](https://longbridge.com/en/news/293143834.md)
- [Acrivon Therapeutics announces availability of new press release](https://longbridge.com/en/news/293383288.md)